Rhythm Pharmaceuticals (RYTM) Earnings Dates, Call Summary & Reports

Compare

583 Followers

Earnings Data

Report Date

May 05, 2026

TBA (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

-0.83

Last Year’s EPS

-0.81

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 13 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 26, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call balanced strong commercial momentum, meaningful year-over-year revenue growth (~+50% FY), expanding international footprint, positive longer-term clinical signals (notably durable bivamelagon 40-week BMI reductions and FDA EOP2 confirmation to proceed to Phase 3), and a healthy cash runway (~$389M) against several operational and development headwinds: FDA-mandated larger/longer trials for new chemical entities (which may extend timelines and cost), inventory dynamics that may dampen near-term revenue, rising operating expenses (2026 non-GAAP OpEx guide ~+35% vs 2025), and remaining uncertainties in genetic substudies and reimbursement timing. Overall the company appears well-capitalized and advancing multiple programs and launches, but will absorb near-term expense and execution risk as it scales.

Company Guidance

The company’s forward guidance focused on 2026 operating spend and near‑term clinical and commercial milestones: annual non‑GAAP operating expenses are guided to $385M–$415M (non‑GAAP R&D $197M–$213M; non‑GAAP SG&A $188M–$202M), a ~35% year‑over‑year increase at the midpoint (~+$104.5M) driven ~30% by next‑gen formulation/clinical supply, ~25% by U.S. commercial build for an HO launch, and ~15% by Japan build‑out; Rhythm ended 2025 with ~$389M cash and short‑term investments, sufficient to fund operations for at least 24 months. Clinical/commercial timing guidance: PDUFA for Acquired HO on March 20, 2026, top‑line Japanese HO cohort and M&A readout due in March, CHMP opinion expected in Q2 and EU approval in H2 2026, plan to complete bioequivalence/DDI/hepatic impairment work and have Phase‑3 supply by year‑end 2026 with Phase‑3 HO initiation targeted by year‑end 2026 (FDA expects a 12‑month randomized trial with patient numbers likely near the 142‑patient setmelanotide trial); PWS full 6‑month data and RM‑718 3‑month data due mid‑year; payer coverage for AHO anticipated within 3–9 months post‑approval. The call also reiterated recent financial/operational metrics: Q4 2025 IMCIVREE revenue $57.3M (U.S. $39M/68%; ex‑U.S. $18.3M/32%), FY2025 revenue $194.8M (~+50% YoY), Q4 cash used in ops ~$25M (FY $116M), Q4 R&D $42M, Q4 SG&A $57.5M, Q4 GAAP loss/share $0.73, 2025 GAAP OpEx $362.3M (non‑GAAP $295.5M), gross‑to‑net U.S. ≈84.6%, Q4 COGS 8.5% (expected 10–12% range), inventory days ~20 (vs. 10–15 norm) with ~1.7M excess vials shipped over dispensed in Q4 (vs ~3M in Q3).

Strong Q4 and Full-Year Revenue Growth

Q4 2025 product revenue of $57.3M, up 12% sequentially; full-year 2025 revenue of $194.8M, approximately +50% year-over-year. Q4 net product revenues were +37% versus Q4 2024.

Improving Patient Base

Sequential quarterly growth driven by ~10% increase in number of patients on reimbursed therapy globally in Q4 2025; U.S. represented 68% ($39M) and ex-U.S. 32% ($18.3M) of Q4 revenue; ex-U.S. revenue increased ~$5.2M or ~40% vs Q3 2025.

Bivamelagon Phase 2 Durable Efficacy at 40 Weeks

40-week open-label data show mean BMI decreases of 10.8% for the 400 mg cohort and 14.3% for the 600 mg cohort (including non-compliant patients); 11 of 14 patients in higher-dose cohorts decreased BMI by ≥10%.

Regulatory Progress for Bivamelagon and HO

End-of-Phase-2 FDA meeting concluded bivamelagon is ready to move to Phase 3; company intends to run a 12-month randomized controlled trial consistent with FDA feedback and integrate full 142-patient dataset into labeling plans.

Multiple Near-Term Catalysts

Key upcoming milestones include PDUFA for Acquired Hypothalamic Obesity (Mar 20, 2026), top-line data from Japanese HO cohort and M&A readout in March, CHMP opinion anticipated in Q2 and potential EU marketing authorization H2 2026.

International Expansion and KOL Activity

IMCIVREE available in >25 countries ex-U.S.; international organization grew to >100 employees across 13 countries; eight new countries added in 2025; 64 abstracts accepted at 12 scientific congresses in 2025.

Commercial Preparedness for AHO Launch

U.S. sales force expanded from 16 to 42 ahead of potential AHO launch; field teams engaged HCPs caring for >2,000 patients diagnosed or suspected with acquired HO; identified ~40 priority medical centers concentrating AHO care.

Solid Balance Sheet and Runway

Ended 2025 with ~$389M in cash equivalents and short-term investments; cash used in operations $116M for the year; company expects cash to fund planned operations for at least 24 months.

Clinical Development Momentum Across Portfolio

RM-718 weekly formulation is enrolling with initial 3-month data expected by mid-year; PWS trial remains on track with 17 of 18 patients continuing on treatment and 6-month data expected mid-year; formulation and phase 3 supply plans on track for next-gen compounds.

Rhythm Pharmaceuticals (RYTM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RYTM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 05, 2026	2026 (Q1)	-0.83 / -	-0.81	―	―	―
Feb 26, 2026	2025 (Q4)	-0.81 / -0.73	-0.72	-1.39% (-0.01)
Nov 04, 2025	2025 (Q3)	-0.71 / -0.82	-0.73	-12.33% (-0.09)
Aug 05, 2025	2025 (Q2)	-0.67 / -0.75	-0.55	-36.36% (-0.20)
May 07, 2025	2025 (Q1)	-0.69 / -0.81	-2.35	65.53% (+1.54)
Feb 26, 2025	2024 (Q4)	-0.69 / -0.72	-0.7	-2.86% (-0.02)
Nov 05, 2024	2024 (Q3)	-0.81 / -0.73	-0.76	3.95% (+0.03)
Aug 06, 2024	2024 (Q2)	-0.71 / -0.55	-0.82	32.93% (+0.27)
May 07, 2024	2024 (Q1)	-2.36 / -2.35	-0.92	-155.43% (-1.43)
Feb 22, 2024	2023 (Q4)	-0.71 / -0.70	-0.75	6.67% (+0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RYTM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2025	$113.74	$104.99	-7.69%
Aug 05, 2025	$90.24	$88.57	-1.85%
May 07, 2025	$62.71	$64.63	+3.06%
Feb 26, 2025	$51.03	$53.32	+4.49%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Rhythm Pharmaceuticals Inc (RYTM) report earnings?

Rhythm Pharmaceuticals Inc (RYTM) is schdueled to report earning on May 05, 2026, TBA (Confirmed).

What is Rhythm Pharmaceuticals Inc (RYTM) earnings time?

Rhythm Pharmaceuticals Inc (RYTM) earnings time is at May 05, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RYTM EPS forecast?

RYTM EPS forecast for the fiscal quarter 2026 (Q1) is -0.83.